SEC Form 4 · accession 0001209191-18-040123

ChemoCentryx, Inc. · CCXI

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Bus. Officer & Treasurer

Period of report

Jun 27, 2018

Accepted (ET)

Jun 29, 2018 · 7:36 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001340652

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Jun 27, 2018	M	800	$6.00	A	24,626	D
Common Stock^F2	Jun 27, 2018	S	800	$13.50	D	23,826	D
Common Stock	Jun 28, 2018	M	24,279	$6.00	A	48,105	D
Common Stock^F2,F3	Jun 28, 2018	S	24,279	$13.674	D	23,826	D
Common Stock	Jun 29, 2018	M	100	$6.00	A	23,926	D
Common Stock^F2	Jun 29, 2018	S	100	$14.10	D	23,826	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F5,F4	$6.00	Jun 27, 2018	M	800	D	Jul 28, 2009	Jul 28, 2019	Common Stock	800	73,991	D
Stock Option (right to buy)^F5,F4	$6.00	Jun 28, 2018	M	24,279	D	Jul 28, 2009	Jul 28, 2019	Common Stock	24,279	49,712	D
Stock Option (right to buy)^F5,F4	$6.00	Jun 29, 2018	M	100	D	Jul 28, 2009	Jul 28, 2019	Common Stock	100	49,612	D

F1Shares sold are associated with stock options that will expire in July 2019.
F2The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F3Reflects the weighted average sale price of the sales sold. The shares were sold in multiple trades at prices ranging from $13.50 to $14.01 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
F4As of June 27, 2018, and prior to this transaction, the exercised options were fully vested.
F5Not applicable.